TOTAL: $1,283.1M

Company
(Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)@

Aastrom Biosciences Inc. (ASTM)

Private placement of common stock

1.18S

$1.1

Aastrom placed 1.18M shares with Isosceles Fund Ltd., raising $1.1M as part of its shelf registration(5/4)

Adolor Corp. (ADLR)

Private placement of newly issued stock

3S

$60

Adolor raised $60M, selling 3M shares to institutional investors (5/30)

AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALXFF)

Private placement of special warrants

N/A

C$8.4 (US$5.4)

AltaRex expects to raise US$5.4M; HSBC Securities Inc. is acting as agent; each special warrant is convertible into one common share of AltaRex (5/25)

Amylin Pharmaceuticals Inc. (AMLN)

Private placement of common stock

3.5S

$35

Amylin raised $35M in a private placement; Lehman Brothers acted as the sole placement agent (5/14)

Bioject Medical Technologies Inc. (BJCT)

Equity financing

1.5S (plus warrants to purchase 0.225S)

$15

Bioject raised $15M in an equity financing round; investors included Merlin Biomed Group, Pequot Capital Management and Franklin Templeton Investments; Leerink, Swann & Co. acted as lead placement agent (5/24)

BioMarin Pharmaceutical Inc. (BMRN)

Private placement of common stock and warrants

4.8S (plus warrants to purchase 0.7S)

$45

BioMarin raised $45M in a 4.8M-share offering at $9.45 per share; warrants to purchase about 700,000 shares at $13.10 apiece also were issued; OrbiMed Advisors LLC led the round; other investors were Franklin Resources Inc., equity4life, MPM BioEquities Fund and Orbitex Management Inc. (5/17)

Cephalon Inc. (CEPH)

Private placement of convertible subordinated notes

N/A

$300

Cephalon raised $300M through a private placement of convertible subordinated notes due 2006; the offering was made through initial purchasers to institutional buyers (5/2)

Cerus Corp. (CERS)

Private placement of common stock

1.5S

$78

Cerus raised $78M through a placement of 1M shares at $52 each with an institutional investor and the sale of 500,000 shares at the same price to Baxter Healthcare Corp.; Morgan Stanley Dean Witter served as placement agent (5/17)

Genzyme Corp. (unit of Genzyme General; GENZ)

Private placement of convertible subordinated notes

N/A

$500

Genzyme plans to sell $500M worth of convertible subordinated notes (5/2)

Lynx Therapeutics Inc. (LYNX)

Private placement of newly issued shares

1.7S

$11.1

Lynx raised $11.1M through the placement of 1.7M shares at $6.37 per share; the funding was self-managed; the round was led by HBK MasterFund LP (5/25)

Medicure Inc. (Canada; CDNX:MPH)

Private placement of units

2.6U

C$2.6 (US$1.7)

Medicure closed the placement with Crocus Investment Fund, Manitoba Science and Technology Fund and Renaissance Capital Manitoba Ventures Fund Limited Partnership (5/31)

MGI Pharma Inc. (MOGN)

Private placement of common stock

4S

$29.2

MGI sold 4M shares of its common stock to U.S. Bancorp Piper Jaffray Inc. for about $29.2M; this leaves MGI with 1M shares on the shelf (5/9)

NeoTherapeutics Inc. (NEOT)

Private placement of common stock

1.4S

$6

NeoTherapeutics raised $6M in the 1.4M-share placement at $4.25 each; the shares were placed with Montrose Investments Ltd. and Strong River Investments Inc. (5/21)

Organogenesis Inc. (AMEX:ORG)

Private placement of common stock

1.9S

$15.4

Organogenesis agreed to sell, from time to time, 1.9M shares to UBS Warburg (5/9)

Phage Therapeutics International Inc. (OTC BB:PTXX)

Equity financing

2.14U

$1.5

Phage raised $1.5M through an investment of seven buyers in exchange for 2.14M units (5/30)

StemCells Inc. (STEM)

Equity financing for 30 months

N/A

­

StemCells entered an agreement with an institutional researcher for up to $30M in equity financing over 30 months (5/11)

SYN X Pharma Inc. (Canada; CDNX:SYY)

Private placement of special warrants

2.14W

$15

SYN X entered into a financing agreement with a syndicate of underwriters led by Sprott Securities Inc. to sell 2.14M special warrants; the company also granted an overallotment option for another 714,286 warrants for a possible $5M more (5/1)

The Medicines Company Inc. (MDCO)

Private

placement of common stock

4S

$41.8

The Medicines Company expects to net $41.8M in a private placement; Robertson Stephens Inc. is the lead placement agent (5/14)

Transgene (France; TRGNY)

Private placement of common stock

4.21S

EUR61.4 (US$54)

Transgene raised net proceeds of US$54M; the shares were acquired by bioMerieux Pierre Fabre and the French Muscular Dystrophy Association (5/25)

Trimeris Inc. (TRMS)

Private placement of common stock

1.4S

$44

Trimeris raised $43.4M net in a private placement (5/8)

VaxGen Inc. (VXGN)

Private placement of convertible preferred stock

0.02S

$20

VaxGen raised $20M through the placement of 20,000 Series A convertible preferred shares convertible into common stock at $23.33 per share; the financing was led by The Palladin Group LP; other investors were Halifax Fund LP, Societe Generale Asset Management and Velocity Investment Partners Inc. (5/24)

Viventia Biotech Inc. (Canada; TSE:VBI)

Equity financing agreement

N/A

C$6 (US$3.9)

Viventia is receiving funding from Dan Family Holdings Ltd. through two investment options: units consisting of one common share and one common share purchase warrant or a convertible debenture investments (5/17)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

N/A = Not available or reported.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange